Compugen Ltd. - Ordinary Shares (CGEN): Price and Financial Metrics
CGEN Price/Volume Stats
| Current price | $0.93 | 52-week high | $1.49 |
| Prev. close | $0.88 | 52-week low | $0.51 |
| Day low | $0.87 | Volume | 64,500 |
| Day high | $0.93 | Avg. volume | 405,805 |
| 50-day MA | $1.07 | Dividend yield | N/A |
| 200-day MA | $0.92 | Market Cap | 80.56M |
CGEN Stock Price Chart Interactive Chart >
Compugen Ltd. - Ordinary Shares (CGEN) Company Bio
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and product candidates primarily in the United States, Europe, and Israel. The company was founded in 1993 and is headquartered in Tel Aviv, Israel.
Latest CGEN News From Around the Web
Below are the latest news stories about COMPUGEN LTD that investors may wish to consider to help them evaluate CGEN as an investment opportunity.
Is Aspira Women's Health (AWH) Stock Outpacing Its Medical Peers This Year?Here is how Aspira (AWH) and Compugen (CGEN) have performed compared to their sector so far this year. |
Compugen to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will be available on demand on the Investor Relations section of Compugen's website at www.cgen.com from Monday, September 11, 2023, 7:00 AM ET for 30 days. |
Has Compugen (CGEN) Outpaced Other Medical Stocks This Year?Here is how Compugen (CGEN) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year. |
Compugen Ltd. (NASDAQ:CGEN) Q2 2023 Earnings Call TranscriptCompugen Ltd. (NASDAQ:CGEN) Q2 2023 Earnings Call Transcript August 7, 2023 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen’s Second Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode. As a reminder, today’s call is being recorded. An audio webcast of this call will […] |
Compugen Reports Second Quarter 2023 ResultsCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on key events since the start of 2023. |
CGEN Price Returns
| 1-mo | -18.42% |
| 3-mo | -18.42% |
| 6-mo | 38.81% |
| 1-year | 41.55% |
| 3-year | -94.28% |
| 5-year | -74.17% |
| YTD | 29.94% |
| 2022 | -83.36% |
| 2021 | -64.49% |
| 2020 | 103.19% |
| 2019 | 174.65% |
| 2018 | -13.20% |
Loading social stream, please wait...